PRP019: Use of Fresh Platelet Rich Plasma With Concentrated Leukocytes or Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial

Sponsor
Istituto Ortopedico Rizzoli (Other)
Overall Status
Recruiting
CT.gov ID
NCT04187183
Collaborator
(none)
132
1
2
53.4
2.5

Study Details

Study Description

Brief Summary

The aim of the study is to compare the triple infiltration of Fresh Platelet Rich Plasma with concentrated Leukocytes against triple infiltration of Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the treatment of Knee Cartilage Degeneration in a Double Blind Randomized Controlled Trial

Condition or Disease Intervention/Treatment Phase
  • Other: Fresh Platelet Rich Plasma with leukocyte
  • Other: Fresh Platelet Rich Plasma without leukocyte
N/A

Detailed Description

Platelet Rich Plasma has a consolidated use in the field of orthopedic surgery to reduce inflammation, promoting bone regeneration and healing of surgical wounds.

Some clinical studies demonstrated the utility of the intra-articular infiltration of Platelet Rich Plasma in the treatment of knee articular cartilage lesions, becoming a common conservative strategies in the management of these diseases.

Actually, there are some different kinds of PRP formulations, in particular, the scientific debate is focusing on the role of Leukocytes and if it is better using fresh or frozen PRP.

At the moment don't exist randomized controlled clinical studies comparing fresh PRP rich in Leukocyte against PRP poor in Leukocyte in the treatment of knee cartilage lesions.

The study has two groups of patients, the first will undergo to three infiltrations of Fresh Platelet Rich Plasma With Concentrated Leukocytes and the second will undergo to three infiltrations of Fresh Platelet Rich Plasma Without Concentrated Leukocytes, each infiltrations will be done weekly.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
132 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Use of Fresh Platelet-rich Plasma With Concentrated Leukocytes or Fresh Platelet-rich Plasma Without Concentrated Leukocytes for Treating Knee Cartilage Degeneration: a Randomized Controlled Trial
Actual Study Start Date :
Jun 23, 2020
Anticipated Primary Completion Date :
Dec 4, 2024
Anticipated Study Completion Date :
Dec 4, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Fresh PRP with concentrate Leukocyte

Three infiltrations of fresh Platelet Rich Plasma with concentrated Leukocytes 1 infiltration weekly, for 3 weeks.

Other: Fresh Platelet Rich Plasma with leukocyte
autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint

Active Comparator: Fresh PRP without concentrated Leukocyte

Three infiltrations of fresh Platelet Rich Plasma without concentrated Leukocyte. 1 infiltration weekly, for 3 weeks.

Other: Fresh Platelet Rich Plasma without leukocyte
autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint

Outcome Measures

Primary Outcome Measures

  1. IKDC-subjective score (International Knee Documentation Committee) [12 month]

    It is a specific subjective rating scale for te knee. Iti s one of the most reliable tools for assessing knee diseases. The survey examines three categories: symptoms, sport activity, knee function.

Secondary Outcome Measures

  1. KOOS score (Knee Injury and Osteoarthritis Outcome Score) [baseline, 2, 6, 12 and 24 months]

    KOOS consists of 5 subscales; Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL). The previous week is the time period considered when answering the questions. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale

  2. EQ-VAS (EuroQol-visual analogue scales) [baseline, 2, 6, 12, 24 months]

    It is a rating scale for assessing the health state of the patient. The scale ranging from 0 (the worst health state) to 100 (the best health state)

  3. EQ-5D (EuroQoL) Current Health Assessment [baseline, 2, 6, 12, 24 months]

    It is a reliable tools for assessing quality of life of the patient

  4. Tegner Activity Level Scale [baseline, 2, 6, 12, 24 months]

    Survey useful for assessing sport activity of the patient. The Tegner activity scale is a one-item score that graded activity based on work and sports activities on a scale of 0 to 10. Zero represents disability because of knee problems and 10 represents national or international level soccer.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Patients with degenerative pathology of the knee cartilage with:
  1. Age between 18 and 75 years;

  2. Unilateral involvement;

  3. Signs and symptoms of degenerative pathology of the cartilage of the knee;

  4. Radiographic or MRI signs of degenerative pathology of the cartilage of the knee (Kellgren-Lawrence 1-4 degrees);

  5. Hemoglobin> 11 g / dl; Platelet count> 150,000 plt / mm3 (recently performed blood count);

  6. No clinically significant electrocardiographic alteration (recently performed ECG).

  7. Patients' ability and consent to actively participate in clinical follow-up;

  8. Signature of informed consent.

Exclusion Criteria:
  1. Patients undergone to intra-articular infiltration of another substance in the previous 6 months;

  2. Patients undergone knee surgery in the previous 12 months;

  3. Patients with malignant neoplasms;

  4. Patients suffering from rheumatic diseases;

  5. Patients suffering from diabetes;

  6. Patients with hematologic diseases (coagulopathies);

  7. Patients on anti-anticoagulant therapy;

  8. Patients suffering from thyroid metabolic disorders;

  9. Patients abusing alcoholic beverages, drugs or drugs;

  10. Body Mass Index> 35;

  11. Patients who have taken NSAIDs within 3 days before taking blood;

  12. Patients with cardiovascular diseases for which the 150 ml blood test would be contraindicated;

  13. Patients with a recently performed blood count with Hb values <11 g / dl and Platelets <150,000 plt / mm3.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istituto Ortopedico Rizzoli Bologna Italy

Sponsors and Collaborators

  • Istituto Ortopedico Rizzoli

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Istituto Ortopedico Rizzoli
ClinicalTrials.gov Identifier:
NCT04187183
Other Study ID Numbers:
  • PRP019
First Posted:
Dec 5, 2019
Last Update Posted:
Apr 11, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 11, 2022